Clinical significance of tryptophan catabolism in follicular lymphoma.


Journal

Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 09 01 2020
revised: 20 08 2020
accepted: 15 09 2020
pubmed: 18 9 2020
medline: 12 1 2021
entrez: 17 9 2020
Statut: ppublish

Résumé

The enzyme, indoleamine 2,3-dioxygenase 1 (IDO), catabolizes tryptophan (Trp) in the kynurenine (Kyn) pathway, and is important in suppressing antitumor immune responses in the tumor microenvironment. With regard to previously untreated patients with follicular lymphoma (FL), we sought to establish the prognostic significance of Trp catabolism in this disease. Serum Trp and Kyn levels in 110 patients with FL were quantified, and their relationship to different clinical parameters studied. IDO expression in the lymph nodes of affected patients was studied. Study participants included 54 males and 56 females (age range 39-86, median 62 years), showing a 5-year overall survival (OS) rate of 78.5%. Patients with a high Kyn level (5-year OS, 65.0% vs. 81.7%; p = 0.026), high Kyn/Trp ratio (71.1% vs. 81.7%; p = 0.002), and low hemoglobin (Hb) level (<12.0 g/dL; p = 0.001; a component of FL international prognostic indexes) demonstrated a significantly shorter OS. Multivariate analysis included the following 10 variables: age, sex, serum β2-microglobulin, Hb, longest diameter of the largest involved node, Ann Arbor stage, serum lactate dehydrogenase, histologic grading, B symptoms, and serum Kyn/Trp ratio; a lower Hb level and a high Kyn/Trp ratio (HR, 3.239; 95% CI, 1.296-8.096) led to a significantly inferior OS. In the microenvironment, some CD11c-positive myeloid dendritic cells but not FL tumor cells were found to produce IDO. Overall, measuring levels of serum Kyn and Trp in individual patients with FL contributed to predicting their prognosis.

Identifiants

pubmed: 32940915
doi: 10.1002/hon.2804
doi:

Substances chimiques

Biomarkers, Tumor 0
Kynurenine 343-65-7
Tryptophan 8DUH1N11BX

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

742-753

Subventions

Organisme : scientific research (B)
ID : 16H04713
Organisme : the Japan Agency for Medical Research and Development
ID : 20cm0106301h0001
Organisme : Scientific Research (B)
ID : 16H04713
Organisme : Japan Agency for Medical Research and Development
ID : 20cm0106301h0001

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Auteurs

Ayako Masaki (A)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Takashi Ishida (T)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yasuhiro Maeda (Y)

Center for Joint Research Facilities Support, Fujita Health University, Toyoake, Japan.

Asahi Ito (A)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Susumu Suzuki (S)

Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan.

Tomoko Narita (T)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Shiori Kinoshita (S)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Takashi Yoshida (T)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Masaki Ri (M)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Shigeru Kusumoto (S)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Hirokazu Komatsu (H)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Hiroshi Inagaki (H)

Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Ryuzo Ueda (R)

Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan.

Ilseung Choi (I)

Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.

Youko Suehiro (Y)

Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.

Shinsuke Iida (S)

Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH